[1] Nagral A, Sarma MS, Matthai J, et al. Wilson's disease: clinical practice guidelines of the Indian national association for study of the liver, the Indian Society of Pediatric Gastroenterology, Hepatology and Nutrition, and the Movement Disorders Society of India. J Clin Exp Hepatol,2019,9(1):74-98. [2] 中华医学会肝病学分会遗传代谢性肝病协作组.肝豆状核变性诊疗指南(2022年版).中华肝脏病杂志,2022,30(1):9-20. [3] 中华医学会神经病学分会帕金森病及运动障碍学组,中华医学会神经病学分会神经遗传病学组.肝豆状核变性的诊断与治疗指南.中华神经科杂志,2008,41(8):566-569. [4] Daniel-Robin T, Bénichou B, Leboucher C, et al. Epidemiology, treatment and burden of Wilson Disease in France: a 10-year analysis of the National Health Insurance Database.Clin Res Hepatol Gastroenterol,2022,46(10):101992. [5] Choe EJ, Choi JW, Kang M, et al. A population-based epidemiology of Wilson's disease in South Korea between 2010 and 2016.Sci Rep,2020,10(1):14041. [6] Yamaguchi H, Nagase H, Tokumoto S, et al. Prevalence of Wilson disease based on genome databases in Japan.Pediatr Int,2021,63(8):918-922. [7] Wallace DF, Dooley JS. ATP7B variant penetrance explains differences between genetic and clinical prevalence estimates for Wilson disease.Hum Genet,2020,139(8):1065-1075. [8] Sandahl TD, Laursen TL, Munk DE, et al. The prevalence of Wilson's disease: an update.Hepatology,2020,71(2):722-732. [9] Cheung KS, Seto WK, Fung J, et al. Epidemiology and natural history of Wilson's disease in the Chinese: a territory-based study in Hong Kong between 2000 and 2016.World J Gastroenterol,2017,23(43):7716-7726. [10] 黄清,王刚.106例肝豆状核变性的临床表型和生存期研究.内科理论与实践,2021,16(5):319-324. [11] Kumari N, Kumar A, Thapa BR, et al. Characterization of mutation spectrum and identification of novel mutations in ATP7B gene from a cohort of Wilson disease patients:Functional and therapeutic implications.Hum Mutat,2018,39(12):1926-1941. [12] Guttmann S, Bernick F, Naorniakowska M, et al. Functional characterization of novel ATP7B variants for diagnosis of Wilson disease.Front Pediatr,2018,6:106. [13] Bandmann O, Weiss KH, Kaler SG. Wilson's disease and other neurological copper disorders.Lancet Neurol,2015,14(1):103-113. [14] Członkowska A, Litwin T, Dusek P, et al. Wilson disease.Nat Rev Dis Primers,2018,4(1):21. [15] Socha P, Janczyk W, Dhawan A, et al. Wilson's disease in children: A position paper by the Hepatology Committee of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition.J Pediatr Gastroenterol Nutr,2018,66(2):334-344. [16] European Association for Study of Liver. EASL Clinical Practice Guidelines: Wilson's disease.J Hepatol,2012,56(3):671-685. [17] Palumbo CS, Schilsky ML. Clinical practice guidelines in Wilson disease.Ann Transl Med,2019,7(Suppl 2):S65. [18] Herrera-Quiñones G, Da Fieno AM, Compta Y, et al. Considerations for optimizing Wilson's disease patients' long-term follow-up.Gastroenterol Hepatol,2022,45(2):146-154. [19] Mohr I, Weiss KH. Biochemical markers for the diagnosis and monitoring of Wilson Disease.Clin Biochem Rev,2019,40(2):59-77. [20] Ryan A, Nevitt SJ, Tuohy O, et al. Biomarkers for diagnosis of Wilson's disease.Cochrane Database Syst Rev,2019,2019(11):CD012267. [21] Chanpong A, Dhawan A. Wilson disease in children and young adults - State of the art.Saudi J Gastroenterol,2022,28(1):21-31. [22] Abbassi N, Bourrahouat A, Bedoya EC, et al. Epidemiology, clinical features, and mortality rate of Wilson disease in Moroccan children: A pediatric case series.Arch Pediatr,2022,29(6):453-458. [23] Russell K, Gillanders LK, Orr DW, et al. Dietary copper restriction in Wilson's disease.Eur J Clin Nutr,2018,72(3):326-331. [24] Schilsky ML. Wilson disease: diagnosis, treatment, and follow-up.Clin Liver Dis,2017,21(4):755-767. [25] Chanpong A, Dhawan A. Long term urinary copper excretion on Chelation therapy in children with Wilson disease.J Pediatr Gastroenterol Nutr,2021,72(2):210-215. |